Cross-sectional associations of resistin, coronary heart disease, and insulin resistance

被引:107
作者
Burnett, MS
Devaney, JM
Adenika, RJ
Lindsay, R
Howard, BV
机构
[1] MedStar Res Inst, Cardiovasc Res Inst, Washington, DC 20010 USA
[2] Childrens Natl Med Ctr, Washington, DC 20010 USA
[3] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow G11 6NT, Lanark, Scotland
关键词
D O I
10.1210/jc.2005-1653
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Recently, resistin was found to be present in atherosclerotic lesions in apoE(-/-) mice. Resistin may be associated with inflammation and atherosclerosis in humans; however, the role of resistin in human disease remains controversial. Objective: This study assesses cross-sectional relationships of resistin with coronary heart disease (CHD). Design, Setting, and Participants: Blood samples from the third examination of the Strong Heart Study (SHS)-the largest study of CHD in American Indians-were used. Cases who had suffered previous myocardial infarction (n=100) were selected randomly from the three SHS sites and matched for study site and sex with controls who had no history of cardiovascular disease (CHD or stroke) (n=100). Main Outcome Measure: Resistin levels by enzyme-linked immunosorbent assay method in cases and controls was the main outcome measure. Results: Resistin levels were higher in cases than controls [median (interquartile range): 3.4 (2.5-4.7) vs. 2.8 (2.1-4.0) ng/ml; P=0.003] and had univariate correlations with age (Spearman r=0.21; P<0.002), fasting insulin (r=0.21; P=0.003), insulin resistance by homeostasis model (r=0.22; P=0.04), albumin to creatinine ratio (r=0.19; P=0.01), and fibrinogen (r=0.34; P<0.0001). Cases were more likely to have diabetes (cases 67%; controls 41%; P<0.0001) but had similar body mass index (cases 31.4 +/- 5.4; controls 30.7 +/- 6.3; P=0.85). Resistin levels were higher in participants with established nephropathy (albumin to creatinine ratio >300 mg/g, n=26) compared with those with normo- (n=122) or microalbuminuria (n=42). In multivariate analysis, nephropathy (P=0.0013) but not previous myocardial infarction (P=0.12) was significantly associated with resistin. Conclusions: Resistin is not independently associated with CHD. Resistin is elevated in survivors of myocardial infarction; however, this reflects a novel association of raised resistin with diabetic nephropathy.
引用
收藏
页码:64 / 68
页数:5
相关论文
共 36 条
  • [1] American Diabetes Association, 1998, DIABETES CARE S1, V21, ps5
  • [2] Regulation of fasted blood glucose by resistin
    Banerjee, RR
    Rangwala, SM
    Shapiro, JS
    Rich, AS
    Rhoades, B
    Qi, Y
    Wang, J
    Rajala, MW
    Pocai, A
    Scherer, PE
    Steppan, CM
    Ahima, RS
    Obici, S
    Rossetti, L
    Lazar, MA
    [J]. SCIENCE, 2004, 303 (5661) : 1195 - 1198
  • [3] The potential role of resistin in atherogenesis
    Burnett, MS
    Lee, CW
    Kinnaird, TD
    Stabile, E
    Durrani, S
    Dullum, MK
    Devaney, JM
    Fishman, C
    Stamou, S
    Canos, D
    Zbinden, S
    Clavijo, LC
    Jang, GJ
    Andrews, JA
    Zhu, JH
    Epstein, SE
    [J]. ATHEROSCLEROSIS, 2005, 182 (02) : 241 - 248
  • [4] Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways
    Calabro, P
    Samudio, I
    Willerson, JT
    Yeh, ETH
    [J]. CIRCULATION, 2004, 110 (21) : 3335 - 3340
  • [5] CHASSON A L, 1960, Tech Bull Regist Med Technol, V30, P207
  • [6] CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
  • [7] de Courten BV, 2004, DIABETES, V53, P1279, DOI 10.2337/diabetes.53.5.1279
  • [8] Serum resistin (FIZZ3) protein is increased in obese humans
    Degawa-Yamauchi, M
    Bovenkerk, JE
    Juliar, BE
    Watson, W
    Kerr, K
    Jones, R
    Zhu, QH
    Considine, RV
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) : 5452 - 5455
  • [9] *DEP HLTH ED WELF, 2002, DHEW PUBL
  • [10] Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease
    Díez, JJ
    Iglesias, P
    Fernández-Reyes, MJ
    Aguilera, A
    Bajo, MA
    Alvarez-Fidalgo, P
    Codoceo, R
    Selgas, R
    [J]. CLINICAL ENDOCRINOLOGY, 2005, 62 (02) : 242 - 249